CERS News and Press, Cerus Corporation From 04/18/24

Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2024 financial results will be released on Thursday, May 2, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss t...

2024-04-12 12:59:27 ET More on Cerus Cerus Corporation (CERS) Q4 2023 Earnings Call Transcript Cerus' soars on meeting main goal of late stage trial for INTERCEPT RBCs in heart surgery patients Cantor picks RCEL as best 2024 medtech idea; bullish on PACB, AXGN, CERS ...

2024-04-12 09:30:05 ET Craig-Hallum analyst issues BUY recommendation for CERS on April 12, 2024 07:19AM ET. CERS was trading at $1.695 at issue of the analyst recommendation. Historical Analyst Recommendations Latest 10 recommendations

Cerus Corporation (Nasdaq: CERS) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of 12-month shelf life for INTERCEPT Platelet Processing Sets, from the date of manufacture, effective immediately. This approval extends the set shelf life by six months from th...

2024-03-19 08:47:37 ET More on Cerus Cerus Corporation (CERS) Q4 2023 Earnings Call Transcript Cantor picks RCEL as best 2024 medtech idea; bullish on PACB, AXGN, CERS Seeking Alpha’s Quant Rating on Cerus Historical earnings data for Cerus Fin...

Trial met the primary efficacy endpoint demonstrating non-inferiority of the incidence of acute kidney injury for INTERCEPT Red Blood Cells compared to conventional red blood cells Cerus Corporation (Nasdaq: CERS) today announced positive topline results for ReCePI, a pivotal Phase 3 cl...

2024-03-06 17:09:23 ET Summary Baker Brothers' 13F portfolio value decreased from $17.35B to $8.79B. The largest five stakes in the portfolio are Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Rhythm Pharma. New stakes include Cerevel Therapeutics, while stake disposals ...

Cerus Corporation (NASDAQ: CERS) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 24.87% on the day to $2.48. Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializ...

2024-03-05 18:43:13 ET Cerus Corporation (CERS) Q4 2023 Earnings Conference Call March 05, 2024, 04:30 PM ET Company Participants Jessica Hanover - Vice President of Corporate Affairs Obi Greenman - President and Chief Executive Officer Kevin Green - Vice Preside...

2024-03-05 16:01:24 ET More on Cerus Cantor picks RCEL as best 2024 medtech idea; bullish on PACB, AXGN, CERS Seeking Alpha’s Quant Rating on Cerus Historical earnings data for Cerus Financial information for Cerus Read the full article on Se...